Cancer Drug Discovery

CAR T Cell Assays for Solid Tumors

Despite showing promising results in hematological malignancies, CAR T cell therapies have limited success in solid tumors. This is largely due to the complex tumor microenvironment (TME) of solid tumors. MIMETAS develops 3D solid tumor models that include factors such as immunosuppressive cells, soluble factors, and ECM stiffness. This enables the assessment of transmigration, recruitment and tumor cell killing by CAR T cells.

CAR T Cell Assay Services

T-cell Extravasation and Migration Towards Cancer Cells

Immune cell migration is crucial for immunotherapy success, especially in treating cancers like metastatic melanoma. MIMETAS' 3D endothelium-on-a-chip model revolutionizes the study of T-cell migration, offering deeper insights for advancing immunotherapy strategies against solid tumors.

App Note: T-Cell Transendothelial Migration

Integrating Stroma and Macrophage Modulation

MIMETAS’ 3D tumor-on-chip model meticulously integrates cancer cells, stromal cells, tumor-associated macrophages (TAMs) and vasculature to mimic the dynamic TME of solid tumors. We provide a flexible and modular platform that enables the combination of different cell types in one and/or different compartments, providing critical insights into how stromal components and TAMs influence immune cell behavior and cancer progression.

Webinar: Disease Modeling for Immuno-Oncology

Assessing Compounds in a 3D Hepatocellular Carcinoma (HCC) Model

HCC is notoriously difficult to treat due to its aggressive behavior, late diagnosis, and intricate tumor microenvironment. MIMETAS developed a screenable HCC-on-a-chip model using patient-derived material. This platform was used to test 28 different treatment conditions within a vascularized microenvironment with cancer-associated fibroblasts. This innovative model enables precise drug interaction studies, offering insights to overcome TME barriers and pave the way for optimized, patient-specific therapies against this formidable cancer.

Download the Poster

High-throughput Screening for Anti-angiogenetic Compounds

Angiogenesis plays a crucial role in cancer development and progression, making it a key target for cancer therapy. However, studying this in vitro can be difficult as most models have limited translatability and lack throughput. MIMETAS recently executed the first large scale organ-on-a-chip screen, screening over 1500 compounds in one go for anti-angiogenic potential and endothelial toxicity in a 3D angiogenesis assay.

Read our Angiogenesis Whitepaper

Read the publication

Modeling Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN is a debilitating side effect of cancer treatments like antibody drug conjugates (ADCs). Leveraging our 3D human motor and sensory models, we enable the precise study of neurotoxic effects and identifying safer ADCs. This improves patient care by mimicking human neuronal responses, offering a scalable, ethical alternative to animal testing.

Download the Poster